Determinants of severity among hospitalised COVID-19 patients: Hospital-based case-control study, India, 2020

PLoS One. 2021 Dec 29;16(12):e0261529. doi: 10.1371/journal.pone.0261529. eCollection 2021.

Abstract

Background: Risk factors for the development of severe COVID-19 disease and death have been widely reported across several studies. Knowledge about the determinants of severe disease and mortality in the Indian context can guide early clinical management.

Methods: We conducted a hospital-based case control study across nine sites in India to identify the determinants of severe and critical COVID-19 disease.

Findings: We identified age above 60 years, duration before admission >5 days, chronic kidney disease, leucocytosis, prothrombin time > 14 sec, serum ferritin >250 ng/mL, d-dimer >0.5 ng/mL, pro-calcitonin >0.15 μg/L, fibrin degradation products >5 μg/mL, C-reactive protein >5 mg/L, lactate dehydrogenase >150 U/L, interleukin-6 >25 pg/mL, NLR ≥3, and deranged liver function, renal function and serum electrolytes as significant factors associated with severe COVID-19 disease.

Interpretation: We have identified a set of parameters that can help in characterising severe COVID-19 cases in India. These parameters are part of routinely available investigations within Indian hospital settings, both public and private. Study findings have the potential to inform clinical management protocols and identify patients at high risk of severe outcomes at an early stage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • C-Reactive Protein / analysis
  • COVID-19 / blood*
  • COVID-19 / epidemiology*
  • Case-Control Studies
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Hospitalization*
  • Hospitals
  • Humans
  • India / epidemiology
  • Interleukin-6 / blood
  • L-Lactate Dehydrogenase / blood
  • Male
  • Middle Aged
  • Procalcitonin / blood
  • Risk Factors
  • SARS-CoV-2*
  • Severity of Illness Index*
  • Young Adult

Substances

  • Fibrin Fibrinogen Degradation Products
  • IL6 protein, human
  • Interleukin-6
  • Procalcitonin
  • fibrin fragment D
  • C-Reactive Protein
  • L-Lactate Dehydrogenase

Grants and funding

The study was funded by the Indian Council for Medical Research under RFC No. ECD/NTF/8/2020-21/COVID dated 10.07.2020. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." We note that one or more of the authors are employed by a commercial company: Independent consultant Dr. DCS Reddy is an independent consultant and had neither commercial nor competing interest. He contributed to designing, technical review of the study methods and review of the manuscript. We have mentioned this in the revised manuscript.